MET and cancer: Recent studies have reported that RTKs other than KIT, such as FLT3-ITD, PDGFRA, MET, and insulin-like growth factor receptor 1 (IGF-1R), also use the Golgi/TGN as their signaling platform in cancer cells (13, 33, 50, 51, 52).